Apple: Consensus Estimates For Q2 2021

Apple (NASDAQ: AAPL) will be reporting their fiscal second quarter on April 28th after market close. Analysts have a consensus $152 12-month price target on the company, via a total of 40 analysts, with 11 analysts having strong buy ratings. 21 analysts meanwhile have buy ratings, 6 have hold ratings, one analyst has a sell rating, and one has a strong sell on the company. The street high comes from Evercore ISI with a $175 price target, and the lowest target sits at $83.

27 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 27 analysts is $76.87 billion; this number has been revised upwards from $74 billion at the start of the year. The highest revenue estimate is $83.2 billion, while the lowest is $70.9 billion.

Onto EBITDA estimates, there are currently only 10 analysts who have second-quarter EBITDA estimates. The mean is currently $22.5 billion, with this number having been revised down from $20.2 billion at the start of the year. Street high is a $23.9 billion EBITDA estimate and the lowest is $20.3 billion.

Analysts estimate that quarterly earnings per share will come in at $0.98, with this number being slightly revised up from $0.90 at the start of the year. Street high is currently $1.09 and the lowest estimate is $0.85 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

CloudMD: Canaccord Reiterates $3.25 Price Target Following Acquisition

This morning, CloudMD Software & Services (TSXV: DOC) announced that they purchased Rx Infinity, an...

Wednesday, January 27, 2021, 04:01:00 PM

Canaccord Slightly Lowers SSR Mining’s Price Target Off Back Of 2022 Guidance

Recently, SSR Mining Inc. (TSX: SSRM) announced full-year 2021 production results, a three-year outlook, and...

Friday, February 11, 2022, 05:10:00 PM

Green Thumb: Analysts Call For $207 Million In Q2 Revenue

Green Thumb Industries (CSE: GTII) announced that they will be reporting their second quarter financials...

Monday, August 9, 2021, 03:36:00 PM

CloudMD: Canaccord Reiterates $3.00 Price Target After Q3 Results

On November 29th, CloudMD Software & Services Inc. (TSXV: DOC) announced its third quarter financial...

Wednesday, December 1, 2021, 03:36:00 PM

Equinox Gold: Mercedes Mine Sale Was “A Favourable Sale Price For A Non-Core Asset”

On December 17th, Equinox Gold (TSX: EQX) announced that they reached an agreement to sell...

Sunday, December 26, 2021, 02:14:00 PM